Form 4: Ironwood Pharmaceuticals Executive Receives Stock Grant
Insider Transaction (Form 4)
Jeffrey Silber, SVP, CMO, Head-Res&Drug of Ironwood Pharmaceuticals Inc, received 137,036 shares of common stock on July 20, 2026.
Summary
- Grant/award: acquired 137,036 Class A Common Stock on July 20, 2026; holds 137,036 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jeffrey Silber — Officer (SVP, CMO, Head-Res&Drug)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-20 | Grant/award | Class A Common Stock | 137,036 | — | — | 137,036 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-20 | Grant/award (137,036 shares) |
Keywords
insider transaction, Form 4, IRWD, IRONWOOD PHARMACEUTICALS INC, neutral, Jeffrey Silber
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.